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ABSTRACT: The mixed lineage leukemia (MLL) gene plays a critical role in epigenetic regulation of gene
expression and is a frequent target of chromosomal translocations leading to leukemia. MLL plant
homeodomain 3 (PHD3) is lost in all MLL translocation products, and reinsertion of PHD3 into MLL
fusion proteins abrogates their transforming activity. PHD3 has been shown to interact with the RNA-
recognition motif (RRM) domain of human nuclear Cyclophilin33 (CYP33). Here, we show that CYP33
mediates downregulation of the expression of MLL target genes HOXC8, HOXA9, CDKN1B, and C-MYC,
inaprolineisomerase-dependentmanner.Thisdownregulation correlateswiththereductionoftrimethylated
lysine 4 of histone H3 (H3K4me3) and histone H3 acetylation. We have structurally characterized both the
PHD3 and CYP33 RRM domains and analyzed their binding to one another. The PHD3 domain binds
H3K4me3 (preferentially) and the CYP33 RRM domain at distinct sites. Our binding data show that binding
of H3K4me3 to PHD3 and binding of the CYP33 RRM domain to PHD3 are mutually inhibitory, implying
that PHD3 is a molecular switch for the transition between activation and repression of target genes. To
explore the possible mechanism of CYP33/PHD3-mediated repression, we have analyzed the CYP33 proline
isomerase activity on various H3 and H4 peptides and shown selectivity for two sites in H3. Our results
provide a possible mechanism for the MLL PHD3 domain to act as a switch between activation and
repression.
The MLL gene is involved in chromosomal rearrangements
that result in a variety of acute leukemias, including de novo
acute leukemia, therapy-induced acute myeloid leukemia, and
most infant leukemia (1-6). Human MLL
1 is a large protein
consisting of 3969 amino acids containing multiple functional
domains, including three AT-hook motifs, a CXXC zinc finger,
two speckled nuclear localization signals, four PHD zinc fingers,
a bromo domain, two FY-rich regions, a transcriptional activa-
tion domain, and a Su(var.)3-9, Enhancer of Zeste, Trithorax
(SET) domain (7-9). MLL regulates expression of a large
number ofgenesduringembryonicdevelopmentand hematopoi-
esis. Like its Drosophila homologue Trithorax (trx), MLL asso-
ciateswithchromatinandwritesanepigeneticmarkonlysine4of
histone H3 (H3K4) through the methyltransferase activity of
theC-terminal SET domain (9, 10).TrimethylationonH3K4
(H3K4me3) is a global mark for transcriptional activation, and
high levels of H3K4me3 are observed in transcriptionally active
regions of MLL target genes (11, 12).
MLL belongs to the Trithorax group (Trx-G) of proteins that
are responsible for epigenetic memory of the transcriptionally
open or active chromatin states in development and differentia-
tion (13). Trx-G proteins antagonize silencing by the Polycomb
group of proteins (Pc-G) (14). The balance of Trx-G and Pc-G
functionstomaintainatranscriptionallyactiveorrepressivestate
has to be elaborately regulated depending on the particular
developmental stage. Direct interaction between MLL and Pc-
G proteins, HPC2 and Bmi-1, has been reported, suggesting that
physical cross-talk between Trx-G and Pc-G proteins is likely to
beinvolvedinthetransitionbetweenactivationandrepressionof
target genes (15). It has been shown that nuclear Cyclophilin33
(CYP33) mediates this transition by binding to the third PHD
finger (PHD3) of MLL (16). CYP33 contains an N-terminal
RRM (RNA-recognition motif) domain and a C-terminal cyclo-
philin domain that has peptidyl-proline isomerase (PPIase)
activity (17, 18). The role of the PPIase activity in the biological
functionofCYP33andthemechanismofhowCYP33modulates
MLL function are still obscure.
PHD fingers are frequently found in chromatin-associated
proteins, recognizing either methylated or unmethylated lysines
of histone proteins (19-25). MLL has four PHD fingers whose
function is mostly unknown. All the PHD fingers as well as the
SET domain are absent in MLL chromosomal translocations
found in leukemia. Recently, it was shown that reinsertion of
PHD3intoMLL-AF9andMLL-ENL fusionproteins abrogates
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immortalization of hematopoietic progenitor cells with a reduc-
tion in the level of expression of critical fusion protein targets
such as HOXA9 or HOXC8, indicating that PHD3 has a crucial
role in MLL function (26, 27).
Herein, we show that CYP33 mediates downregulation of the
expression of MLL target genes HOXC8, HOXA9, CDKN1B,
and C-MYC, in a PPIase-dependent manner. This downregula-
tion correlates with reduction of trimethylated lysine 4 of histone
H3(H3K4me3)andhistoneH3acetylation.Wehavestructurally
characterized both the PHD3 and CYP33 RRM domains using
NMR spectroscopy. Chemical shift perturbation analysis, Ala
mutagenesis,andisothermaltitrationcalorimetryhavebeenused
to show that H3K4me3 and CYP33 RRM bind at distinct sites
on PHD3. A similar analysis with the RRM domain shows that
PHD3 binds on a site that overlaps with the canonical RNA
bindingsiteontheCYP33RRMdomain.Ourbindingdatashow
that binding of H3K4me3 to PHD3 and binding of the CYP33
RRM domain to PHD3 are mutually inhibitory, implying that
PHD3 isa molecular switchfor the transition betweenactivation
and repression of target genes. To explore the possible mechan-
ism of CYP33/PHD3-mediated repression, we have analyzed
CYP33prolineisomeraseactivityonvariousH3andH4peptides
and shown selectivity for two sites in H3. Our results provide a
possible mechanism for the MLL PHD3 domain to act as a
switch between activation and repression.
EXPERIMENTAL PROCEDURES
Protein and Peptide Preparation. DNA encoding MLL
PHD3[A1564-H1628ofhumanMLL(gi56550039)]wascloned
intothe pGEX-4T-1 vector betweenthe BamHIsiteandthe NotI
site. Recombinant PHD3 was expressed in Escherichia coli BL21
cells grown in LB or EMBL medium. Samples for NMR experi-
mentswerepreparedbyadditionofappropriateisotopestomini-
mal medium. All the media used for PHD3 expression included
100 μM zinc chloride; 0.8 mM IPTG was used to induce expres-
sion when OD600 reached 0.6-0.7, and cells were subsequently
grown for 4 h at 30  C. The proteins were initially purified by
affinitychromatographyonaGlutathioneSepharose4Bcolumn.
The eluate was cleaved by thrombin to remove the GST tag and
then dialyzed against 50 mM Tris (pH 8.0), 50 mM NaCl, 3 mM
DTT, and 100 μMZ n C l 2. Proteins were further purified by ion-
exchange chromatography on a DEAE-Sepharose column. Full-
length CYP33 (gi 4406227) and the RRM domain spanning
residues T3-K83 were cloned into the pGEX-4T-1 vector
between the BamHI site and the NotI site. The proteins were
expressed in E. coli BL21 cells grown in LB medium or EMBL
medium with appropriate isotope labeling. CYP33 RRM was
induced by 0.8 mM IPTG at 37  C. CYP33 was induced by
0.8 mM IPTG at 25  C.Cellswereallowedtogrow for4 h before
being harvested. The proteins were initially purified by GST tag
affinity chromatography. The eluate was cut with thrombin,
dialyzed against 50 mM Tris (pH 8.0), 50 mM NaCl, and 1 mM
DTT, and finally purified by ion-exchange chromatography
using DEAE-Sepharose. All the mutants were generated using
the QuickChange site-directed mutagenesis kit (Stratagene,
La Jolla, CA). Histone peptides with or without lysine methylation
[H3 (residues 1-15 with un-, mono-, di-, or trimethylated K4),
H3K9me3 (residues 1-15), H3K27me3 (residues 22-32),
H3K36me3 (residues 31-41), H3K79me3 (residues 74-84),
and H4K20me3 (residues 15-25)] for binding assays were synthe-
sized by New England Peptide LLC (Gardner, MA), Biosynth-
esis (Lewisville, TX), and the Keck Facility at Yale University
(New Haven, CT). A tyrosine was added to the end of the
H3K4me1/2/3 peptides, and the concentration was determined
by measuring the UV absorbance at 280 nm.
NMRSpectroscopy.Two-dimensional(2D)
15N-
1HHSQC,
three-dimensional (3D) HNCACB, 3D CBCA(CO)NH, 3D HNCO,
and 3D HNHA spectra were acquired for backbone assign-
ment. 2D
13C-
1H HSQC, 3D CC(CO)NH-TOCSY, 3D HCC-
(CO)NH-TOCSY, and 3D HCCH-TOCSY spectra were acquired
for side chain assignment. All NMR experiments were performed
at 30  C on a Varian 600 MHz instrument equipped with a cryo-
genicprobe.AllNMRsampleswerepreparedin25mMpotassium
phosphate (pH 6.9), 50 mM NaCl, 1 mM DTT, 1 mM sodium
azide, and 5% (v/v) D2O. Additional DTT (up to 3 mM) and
100 μMZ n Cl 2were added to anyNMR samplecontaining PHD3.
AlignmentforRDCmeasurementswasdeterminedwith polyacryl-
amide gels (28) made of zwitterionic copolymers based on 50%
content of a 1:1 APTMAC/acrylic acid mixture and 50% acryla-
mide; 9% of the initial concentration of the copolymer was used.
Structure Calculations. The structure calculations for
PHD3 and CYP33 RRM were conducted with the same proce-
dure unless otherwise specified. Interproton distance constraints
wereobtained from NOEcross-peak assignmentsin3D NOESY
spectra. Initial semiautomatic NOE assignment and structure
calculation were performed with CYANA (29). After automatic
NOE assignment, only unambiguous NOEs were selected, and
ambiguous NOEs were manually examined and assigned. As-
signed NOEs were then categorized into four groups: 1.8-2.8,
1.8-3.3, 1.8-4.2, and 1.8-5.5 A ˚ for structure calculation. φ and
ψ dihedral angle restraints were generated by TALOS prediction
basedonCR,Cβ,C 0,andNchemicalshifts(30).
3JHNHAcoupling
constant restraints were calculated via comparison of the in-
tensities of diagonal and cross-peaks in a 3D HNHA spec-
trum (31). Three sets of RDCs (
1DHN,
1DNC0,a n d
1DC0CR)w e r e
measured using TROSY-HNCO experiments (32). Initial values
of the axial (Da)a n dr h o m b i c( R) components of the alignment
tensor were estimated from a histogram of RDC distribution,
and final optimized Da and R values were obtained by iterative
fitting of the measured RDCs to the preliminary structure using
PALES (33). Zinc constraints have been used in the final
structural refinement of PHD3 for zinc coordination by the side
chains of seven cysteines and one histidine.
NMR Titration and Chemical Shift Perturbation Anal-
ysis.
15N-
1H HSQC spectra were recorded for probing inter-
actionsbetweenPHD3andhistonepeptides.FortheH3K4bind-
ing studies, 100 μM PHD3 was titrated with 100, 200, 400, 800, and
1600 μM histone H3K4me1/2/3.
15N-
1H HSQC spectra were
recorded at each titration point to calculate chemical shift changes
of the PHD3 residues. To identify the CYP33 RRM-binding site
on PHD3, [U-
15N,
13C,
1H]PHD3 was mixed with unlabeled
CYP33 RRM. Backbone chemical shifts were assigned using 2D
HSQC, 3D HNCO, 3D HNCACB, and 3D CBCA(CO)NH
spectra. Average chemical shifts from each spectrum were used to
calculate chemical shift perturbation upon complex formation.
Similarly, the complex of [U-
15N,
13C,
1H]CYP33 RRM mixed
with unlabeled PHD3 was used to calculate chemical shift pertur-
bation of CYP33 RRM upon PHD3 binding. Combined chemical
shift changes for each residue were calculated using the equation
Δδtot =[ ( wNΔδN)
2 þ (wHΔδH
N)
2]
1/2,w h e r eΔδH
N and ΔδNa r e
thechemicalshiftdifferencesintheH
NandNresonances,respecti-
vely. Weighting factors (wN and wH) of 0.154 and 1 were used for
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Isothermal Titration Calorimetry. ITC experiments were
conducted on a VP-ITC MicroCalorimeter system at 25  C.
Protein samples were dialyzed against 25 mM potassium phos-
phate (pH 7.2), 50 mM NaCl, 1 mM DTT, and 100 μMZ n C l 2
and then centrifuged and degassed prior to use. In each experi-
ment, 8 μL aliquots of a titrant (CYP33 RRM or the H3K4me3
peptide) solution were added 30 times to PHD3. Data were
corrected for dilution enthalpy and then were fit to a one-site
binding model using Origin 7.0.
Peptidyl-Proline Isomerase Activity Assay. The PPIase
assay was conducted as described previously (34). Pentapeptides
with C-terminal pNA corresponding to H3P16, H3P30, H3P38,
and H4P32 were purchased from Biosynthesis (Lewisville, TX).
The peptides were dissolved in TFE containing 470 mM LiCl to
achieve a final peptide concentration of 10 mM. Five milligrams
of bovine chymotrypsin (Sigma-Aldrich) was dissolved in 10 mL
of the buffer containing 50 mM Tris-HCl (pH 8.0) and 100 mM
NaCl.The buffersolution withchymotrypsin waschilled at4  C,
and 10 μL of peptide solution was added to 1 mL of a chilled
buffer solution to initiate the reaction. The progress of the
reaction was monitored by measuring the absorbance at 390
nm using a GenesysII spectrometer (Spectronics). For CYP33-
treated samples, 40 nM CYP33 was added to the reaction buffer
before peptides were added.
RT-PCR. R191A and F196A mutations in the PPIase active
site were introduced by site-directed mutagenesis in the CYP33
coding sequence to create a PPIase dead CYP33 (P. Breslin,
unpublished methods). The resulting polypeptide fused to GST
and expressed from bacteria was tested for proline isomerase
activity by chymotrypsin cleavage of a Suc-AAPF-pNA sub-
strate.Thefirst-orderisomerizationrateusingthemutantprotein
was5.7%oftheoneobtainedforwild-typeCyp33(J.Solankiand
R. Schultz, unpublished observations). HEK293T cells were
transfected with pCEP4 plasmid constructs expressing FLAG-
tagged wild-type or the PPIase mutant CYP33 using Lipofect-
amine 2000 (Invitrogen). After 48 h, RNA was harvested using
Trizol (Invitrogen) and reverse-transcribed using a High-Capacity
cDNA Reverse Transcription kit (Applied Biosystems). Quanti-
tative PCR was performed in triplicate using GoTaq qPCR
Master mix (Promega) on an Applied Biosystem 7300 system.
Expression levels of HOXC8, HOXA9, CDKN1B,a n dC-MYC
cDNAs were normalized to β2M cDNA by the comparative Ct
(cycle threshold) method.
Chromatin Immunoprecipitation. HEK293T cells were
transfected with vector control or pCEP4-CYP33 using lipofect-
amine. After transfection for 48 h, cells were fixed in formalin
and ChIP was performed against anti-histone H3, anti-H3K4me3,
anti-acetylated histone H3 (acetylated at lysines 9 and 14), and
IgG antibodies (Millipore), using the Magna ChIP kit from
Upstate. The ChIP DNA was used as a template for quantitative
PCR at the MLL target gene promoters. The fold occupancy of
histone H3, H3K4me3, and H3 acetylation at MLL target gene
promoters was normalized to input DNA levels.
Primer Sequences. RT-PCR: HOXC8 30UTR (forward),
50TGGAAACCTGAAGGAGATGTGGGT30; HOXC8 30-
UTR(reverse),50AAACAGCGAAGGAGAGGAAGGCAT30;
HOXA9 (forward), 50TCCCACGCTTGACACTCACACTTT30;
HOXA9 (reverse), 50AGTTGGCTGCTGGGTTATTGGGAT30;
CDKN1B (RT forward), 50CCGGCTAACTCTGAGGACAC30;
CDKN1B (RT reverse), 50CTTCTGAGGCCAGGCTTCTT30;
C-MYC (RT forward), 50CCTACCCTCTCAACGACAGC30;
C-MYC (RT reverse), 50CTCTGACCTTTGCCAGGAG30;
CYP33(forward),50GTTTTCTGGGAAGACGCTTG30;CYP33
(reverse), 50ATTTGAGCGGGCCTTTTTAG30; β2M (forward),
50TGCTGTCTCCATGTTGATGTATCT30; β2M (reverse),
50TTGATTTTGGAGGGATCTCG30.C h I P :HOXC8 promoter
(forward), 50AGTCTGAGGAATTCGCCTGGGCTGTTA30;
HOXC8promoter (reverse),50CGCTCCTCACTGTCGGTAG-
GTAGA30; CDKN1B promoter (forward), 50CCGGCTAACT-
CTGAGGACAC30; CDKN1Bpromoter (reverse), 50ATACGC-
CGAAAAGCAAGCTA30.
RESULTS
Solution Structure of PHD3. The solution structure of
PHD3 was calculated using constraints obtained from multi-
dimensional heteronuclear NMR spectroscopy. The constraints
for structure determination and the structural statistics are
summarized in Table 1 of the Supporting Information. NMR
data and atomic coordinates have been deposited in the Bio-
MagResBank and the RSCB Protein Data Bank. The final ensemble
of 10 conformers of 100 calculated structures was selected by
lowest energy with a backbone root-mean-square deviation
(rmsd) of 0.54 A ˚ . The solution structure suggests that the overall
fold of PHD3 is similar to that of previously determined PHD
fingers, coordinating two zinc atoms in one structural entity
(Figure 1). Two zinc-binding clusters are formed by C1569,
C1572, H1596, and C1599 and by C1588, C1591, C1621, and
C1624. The structure consists of a small double-stranded anti-
parallel β-sheet, two short R-helices, and the four loops connect-
ing them (Figure 1B). The β-sheet is located between two zinc
clusters as istypically found inother PHD fingers. L1isnot well-
defined in our NMR ensemble.
15N T1 and T2 relaxation time
measurements showed that L1 is flexible in solution (data not
shown).
PHD3 Selectively Binds H3K4me3. PHD3 is very similar
in sequence and structure to PHD fingers that recognize a
methylated lysine in histone tails (Figure 2). PHD fingers that
recognize a methylated lysine have an invariant tryptophan on
the β-sheet, whereas PHD fingers that bind exclusively to an
FIGURE 1: Solution structure of PHD3. (A) Stereoview of an en-
semble of 10 conformers. (B) Ribbon representation of the lowest-
energy structure showing secondary structural units. The side chains
of the residues coordinating the two zinc atoms (orange) are colored
blue.Article Biochemistry, Vol. 49, No. 31, 2010 6579
unmethylated lysine do not have this tryptophan (Figure 2A).
Recent structures of PHD finger and H3K4me3 complexes
revealed that this tryptophan is critical for the recognition of
methylated lysine (22, 35). PHD3 also has a tryptophan, which is
located at the same position as seen in known structures of PHD
finger-H3K4me3 complexes (Figure 2B). Because the sequence
and structural comparison strongly suggested that PHD3 might
recognize a methylated lysine, the ability of PHD3 to recognize
methylatedlysinepeptideswasscreenedusingaseriesof
15N-
1H
HSQC experiments. Synthetic histone peptides with trimethyla-
tion on H3 K4, H3 K9, H3 K27, H3 K79, and H4 K20 were
titrated into PHD3 and monitored for chemical shift perturba-
tion. Only the H3K4me3 (residues 1-15) peptide induced
chemical shift changes of PHD3, whereas the others did not,
indicating that PHD3 interacts with H3K4me3 (Figure 3A).
Furthermore,PHD3exhibiteddifferentialaffinityformono-,di-,
andtrimethylated H3K4,asobserved inthePHDfingers already
shown to bind H3K4me3. The difference in the magnitude of the
chemical shift changes of a representative amide resonance
(Q1587) on
15N-
1H HSQC spectra upon titration with mono-,
di-, and trimethylated H3K4 indicates that PHD3 preferentially
binds to trimethylated H3K4 (Figure 3B). The binding stoichio-
metry and affinity of the PHD3-H3K4me3 interaction were
determined by ITC. PHD3 binds H3K4me3 with a 1:1 stoichio-
metry and a Kd of ∼30 μM (Figure 3C). This binding preference
of the MLL PHD3 domain was also very recently reported by
others (36).
We next identified the H3K4me3 binding site on the basis of a
structural comparison and chemical shift perturbation data. The
structure of PHD3 was compared to the structure of the BPTF
PHD-H3K4me3 complex (PDB entry 2F6J). The backbone
atoms of the core region from K1584 to E1600 of PHD3 were fit
to the core region of the BPTF PHD with a backbone rmsd of
0.93 A ˚.The overallfolds of the two PHDfingers areverysimilar,
and the conserved tryptophan of each PHD superimposes well
(Figure 4A). The BPTF PHD has an H3K4me3-docking groove
with two pockets for the side chains of R2 and trimethylated K4
of H3. The same groove is found in the structure of PHD3,
suggesting the binding site for H3K4me3 (Figure 4B). The
chemical shift changes upon H3K4me3 binding also supported
thebindingsitepredictedbystructuralcomparison.WhenPHD3
was titrated with H3K4me3, the backbone resonances of the
residuesthatformthegroovewerebroadenedoutorsignificantly
shifted (Figure 4C), indicating that this region is involved in the
interaction with H3K4me3. To confirm the binding site and that
the conserved tryptophan is essential in recognizing H3K4me3,
wemutatedittoalanineandprobedtheinteractionbyNMR.No
significant change in chemical shift was observed on the
15N-
1H
HSQCspectrumofPHD3-W1594AuponadditionofH3K4me3,
indicatingthattheinteractionbetweenthemutantandH3K4me3
is negligible (Figure 4D).
Identification of Recognition Sites for the Interaction
between PHD3 and CYP33 RRM. It was shown previously
that PHD3interactswithCYP33 RRM using a yeasttwo-hybrid
assay, co-immunoprecipitation, and GST pull-down (16). To
identify the binding site on PHD3 for CYP33 RRM, chemical
shift perturbation of backbone resonances of PHD3 was ana-
lyzed upon titration with CYP33 RRM. We identified the
residues at the binding interface by plotting the combined
chemical shift changes of H
N and N versus the residue number
(Figure 5A) and mapping them onto the structure of PHD3
(Figure 5B). In particular, chemical shifts of residues in R1, R2,
and L4 showed significant perturbations, indicating that this
region is likely the site of interaction. Interestingly, the MLL
PHD3 domain has a longer L4 than other chromatin-associating
PHD fingers shown in Figure 2A, implying a functional role
otherthan H3K4me3binding. Toconfirmthe importance of this
loop for CYP33 RRM binding, we mutated two residues in L4,
V1617, which showed the most significant change in chemical
shift upon CYP33 RRM titration, and Y1619, an aromatic
residuefrequentlyfoundatprotein-proteininterfaces,toalanine
andmeasuredthebindingaffinityforthemutantsusingITC.The
V1617A mutation decreases the affinity by ∼6.2-fold (Figure 5C).
The
15N-
1H HSQC spectrum of V1617A showed that this
FIGURE 2: Sequence and structural comparison of PHD fingers. (A) Sequence alignment of the MLL PHD3 finger with PHD fingers of
chromatin-associating PHD fingers. Zinc-coordinating residues are colored orange, and the invariant tryptophan is colored red. AIRE and
HBC80bindtoanunmethylatedlysine4onhistoneH3(20,43).ING2,Yng1,andBPTFbindtoamethylatedlysine4onhistoneH3(22,35,44).
(B) Structure comparison of the MLL PHD3 finger (left) with PHD fingers of BPTF (middle, PDB entry 2F6J) and ING2 (right, PDB entry
2G6Q). The backbone of histone H3 is colored blue, and H3K4me3 is colored violet. The side chain of the invariant tryptophan is colored red.6580 Biochemistry, Vol. 49, No. 31, 2010 Park et al.
mutation does not affect the structural stability of PHD3
(Figure S1 of the Supporting Information). The Y1619A muta-
tion also showed decreased affinity, but the
15N-
1H HSQC
spectrum indicated that the impaired binding is probably caused
by disruption of the overall fold (Figure S1 of the Supporting
Information).
The binding site on CYP33 RRM for PHD3 was also
identified.First,conventionalNMRexperimentswereconducted
to assign resonances of CYP33 RRM and determine the solution
structure. The detailed structural data and NMR statistics for
structure calculation are described in Table 2 of the Supporting
Information.AcrystalstructureoftheCYP33RRMdomainwas
also reported recently by others (37). By identifying residues that
experienced large chemical shift perturbations upon complex
formation, we identified the binding site on CYP33 RRM for
PHD3 (Figure 5D). Many residues on the surface composed of
the central β-sheet and the loop between β2a n dβ3 participate in
PHD3 binding (Figure 5E). To assess the role of the residues in
thisregioninrecognitionofPHD3,L39,K45,R47,F49,andF51
were mutated to alanine, and the affinities of the mutants for
PHD3 were measured by ITC. Among them, L39A and F49A
showed affinities decreased by ∼4.3- and ∼14-fold, respectively,
without disrupting the structure as assessed by
15N-
1H HSQC
spectra (Figure S2 of the Supporting Information). In contrast,
K45A and R47A did not abrogate the interaction, and the F51A
mutation disrupts the structure of CYP33 RRM (data not
shown). We also identified the RNA-binding site of CYP33
RRM by probing chemical shift perturbation upon titration of
RNA (Figure S3 of the Supporting Information). Interestingly,
the binding site of CYP33 RRM for PHD3 generally overlaps
with the canonical RNA-binding site, suggesting that PHD3
competes with RNA. The biological relevance of RNA binding
of CYP33 RRM and potential competition with PHD3 is an
important area for future study.
CYP33 Represses Transcription of MLL Target Genes
and Changes H3K4 Methylation and H3 Acetylation
Levels. MLL regulates anumber ofgenes,includingHOXgenes
(e.g.,HOXC8andHOXA9)andnon-HOXgenes(e.g.,CDKN1B
and C-MYC)( 38-41). To assess the general role of CYP33 on
MLL target genes, the expression of HOXC8, HOXA9,
CDKN1B,a n dC-MYC was monitored in HEK293T cells over-
expressing CYP33. The expression level was quantified by real-
time RT-PCR at 48 h after transfection of an empty vector or a
CYP33-containing vector. High-level expression of CYP33 was
confirmedbyquantitativeRT-PCR(FigureS4oftheSupporting
Information). Expression levelsofMLL targetgenes andCYP33
werenormalizedagainstβ2M,whoseexpressionisnotinfluenced
by CYP33. All MLL target genes tested here were markedly
downregulated upon CYP33 expression, indicating that CYP33
negatively regulates the function of MLL (Figure 6A).
We next examined the level of H3K4me3, which is an activa-
tion mark written by MLL, on MLL target genes. Chromatin
immunoprecipitation experiments were performed 48 h after
transfection of HEK293T cells with an empty vector or a
CYP33-containingvector.CYP33overexpressionwasconfirmed
by quantitative RT-PCR (Figure S4 of the Supporting Infor-
mation). The H3K4me3 mark is reduced by CYP33 over-
expression at the promoter regions of CDKN1B and HOXC8
(Figure 6B). In addition, the overall acetylation level of H3 on
CDKN1B is also reduced by CYP33 (Figure 6B). The increase in
H3concentrationcorrespondstoahighernucleosomedensityon
the CDKN1B and HOXC8 promoters after transcriptional silen-
cing.Taken together,CYP33 overexpression leads toa changein
histone modifications and chromatin structure consistent with a
switch from gene activation to repression, resulting in down-
regulation of the expression of MLL target genes.
FIGURE 3: PHD3 preferentially binds H3K4me3. (A) Overlay of
15N-
1H HSQC spectra of PHD3 in the absence (red) and presence
(blue) of H3K4me3. (B) Titration plot based on the chemical shift
changes of the Q1587 H
N resonance of PHD3. Chemical shift
changes upon addition of mono-, di-, and trimethylated H3K4 were
plotted asa function ofthe molar ratio. (C) ITC measurement of the
binding of PHD3 toH3K4me3. Datafromaddition of8 μLa l i q u o t s
of 745 μM peptide to a solution of 65 μM PHD3 are shown.Article Biochemistry, Vol. 49, No. 31, 2010 6581
Proline Isomerization Activity Is Necessary for CYP33-
Mediated Downregulation of MLL Target Genes. CYP33
has a cyclophilin domain that has PPIase activity as found in
other cyclophilin family proteins (17). It has been previously
reported that downregulation of HOXC8 by CYP33 overexpres-
sion can be inhibited by cyclosporin A, a general inihibitor of
cyclophilins’ PPIase activity (15). To determine more specifically
theroleoftheCYP33PPIaseactivityinnegativeregulationofthe
transactivation function of MLL, a CYP33 mutant (R191A/
F196A) that lacks PPIase activity was employed. The expression
of HOXC8, HOXA9, CDKN1B,a n dC-MYC was quantified in
HEK293T cells transfected with either the mutant or wild-type
CYP33 expression vector. All four genes tested were no longer
downregulated upon mutantCYP33 expression,even though the
expression level of the mutant CYP33 was higher than for wild-
type CYP33, indicating that the CYP33 PPIase activity is
essential for repression of MLL target genes (Figure 7A,B).
The in vivo substrates of CYP33 are not known. Because
CYP33 is recruited to the multiprotein MLL complex via the
PHD3-RRM interaction, possible substrates include MLL
itself, a protein recruited to the MLL complex, and a histone.
Recently, it was shown that the proline isomerase Fpr4 targets
H3 P38 to alter the pattern of modifications at K36, thereby
alteringgeneexpression (42).OnthebasisofanalogytoFpr4,we
tested PPIase activity of CYP33 on four prolines of histone tails:
H3P16, H3 P30,H3 P38, and H4 P32. The prolineisomerization
activity of proteins can be measured using a chymotrypsin-
coupled assay with synthetic pentapeptides in which candidate
prolines are followed by a phenyalanine and p-nitroanaline
(pNA) group (Figure 7C). Similar to Fpr4, CYP33 shows little
tonoactivityforH4P32andhighactivityforH3P30(Figure7D).
In contrast to Fpr4, CYP33 has activity for H3P16 and shows
only very modest activity for H3P38. Thus, CYP33 does show
prolineisomeraseactivityonH3histonetailprolinesanddisplays
substrate specificity that differs from that of Fpr4.
CYP33 RRM and H3K4me3 Binding to PHD3 Are
MutuallyInhibitory. Onthebasisofbindingsiteidentification,
PHD3utilizestwoseparatesurfacesforthebindingofH3K4me3
and CYP33 RRM (Figure 8A). To confirm this, we have tested
the binding of two mutants in PHD3 to both H3K4me3 and
CYP33 RRM. W1594A, which impairs H3K4me3 binding, does
not significantly affect the affinity for the RRM domain. ITC
datashowedthatthe Kdofthe W1594A PHD3forCYP33RRM
is 19.6 μM, which is ∼1.3-fold weaker than that of the wild type
(14.7 μM) (Figure 8B). Similarly, V1617A PHD3, which abro-
gatesRRMbindingby∼6.2-fold,doesnotsignificantlyaffectthe
FIGURE 4: IdentificationoftheH3K4me3recognitionsiteonPHD3.(A)SuperimpositionoftheMLLPHD3fingerwiththeBPTFPHDfingerin
complexwithH3K4me3 (PDBentry2F6J). TheMLL PHD3fingeriscoloredblue,theBPTFPHDfingergreen,andtheN-terminalH3tailred.
The side chain of the consensus tryptophan of each PHD finger is colored yellow. The side chain of the K4 of histone H3 is colored blue.
(B) Surface comparison of the MLL PHD3finger (right) with the BPTF PHD finger in complex withH3K4me3 (left). The N-terminal H3 tail is
colored red,and the sidechains ofR2 and K4are colored blue. Residues whose backbone resonance was broadened out (yellow) orsignificantly
perturbed(red)inpanelCaremappedonthestructureoftheMLLPHD3finger.(C)Plotofchemicalshiftdifferences(Δδtot)ofthebackboneH
N
and N resonances of PHD3 between the free and H3K4me3-bound state. Asterisks indicate the residues whose resonances are broadened out.
(D) Overlay of
15N-
1H HSQC spectra of the W1594A mutant in the presence (blue) and absence (red) of H3K4me3.6582 Biochemistry, Vol. 49, No. 31, 2010 Park et al.
affinity for H3K4me3 (Figure 8B). The Kd of V1617A PHD3 for
theH3K4me3peptideis52.4μM,whichis∼1.7-foldweakerthan
the wild-type value (30.9 μM).
With two binding sites on PHD3, it is possible that the two
proteins bind with no influence on one another or that the
bindingofonecaninfluencethebindingoftheother.IfthePHD3
domain does indeed act as a switch, the latter behavior would be
expected. In particular, we would predict that binding of one
protein will inhibit the binding of the other. To test this, we have
taken ITCmeasurements of the binding ofH3K4me3 to a PHD3-
CYP33RRMcomplexandofCYP33RRMtoaPHD3-H3K4me3
complex. Consistent with our prediction, PHD3-H3K4me3
binding is significantly influenced by the presence of the RRM
domain, resulting in an ∼5.7-fold increased Kd (Figure 8C).
Similarly, PHD3 saturated with H3K4me3 was titrated with
CYP33, in which case an ∼4.4-fold increase in the Kd for the
PHD3-CYP33 RRMinteractionwasobserved(Figure8C).These
dataclearlyshowthatthebindingofthetwopartners,H3K4me3
and CYP33 RRM, is mutually inhibitory; i.e., increasing con-
centrations of CYP33 will displace PHD3 from H3K4me3.
DISCUSSION
MLL plays a key role in controlling the expression of devel-
opmentally regulated genes.To dothis, it mustbe able tostrike a
delicate balance between activation and repression. Our results
suggest that the PHD3 domain of MLL acts as a key switch
between activation and repression (see Figure 9). PHD3 binds
both H3K4me3 and CYP33 on distinct surfaces on the structure
of PHD3. This binding is mutually inhibitory, so increased levels
of CYP33 will cause PHD3 to dissociate from H3K4me3, a key
epigeneticmarkforactivation.LowlevelsofCYP33wouldresult
FIGURE 5: IdentificationofthebindingsitesfortheinteractionbetweenPHD3andCYP33RRM.(A)Plotofchemicalshiftchanges(Δδtot)ofthe
backboneH
N and N resonances of PHD3uponCYP33 RRM titration.Asterisks indicate the residueswhose resonances are broadened out. (B)
Residues whose backbone resonance were broadened out (yellow) or significantly perturbed (red) in panel A are mapped on the structure of
PHD3. The side chain of V1617 is colored green. (C) ITC measurements of the binding of CYP33 RRM (left) to wild-type PHD3 and to the
V1617A mutant (right). Wild-type PHD3 (62 μM) was titrated with 755 μM CYP33 RRM, and 98 μM V1617A was titrated with 1 mM CYP33
RRM.(D)Plotofchemicalshiftchanges(Δδtot)ofthebackboneH
NandNresonancesofCYP33RRMuponPHD3titration.(E)Residueswhose
backboneresonancesweresignificantlyperturbed(red)inpanelDaremappedonthestructureofCYP33RRM.Thelowest-energystructurefrom
calculation is shown as a ribbon-and-arrow diagram.Article Biochemistry, Vol. 49, No. 31, 2010 6583
inbindingofPHD3totheH3K4me3mark.Althoughthespecific
role of the binding of MLL PHD3 to H3K4me3 remains to be
elucidated, one possible scenario is that this binding is required
for propagation of the H3K4me3 mark by the MLL methyl-
transferase activity. In this scenario, MLL could bind to trimet-
hylated lysine 4 on a modified histone H3 and target an unmodi-
fiedhistoneH3moleculeonthesameoraneighboringnucleosome
for trimethylation (see Figure 9). High levels of CYP33 would
result in dissociation of PHD3 from H3K4me3, preventing the
methylation of new histones and making the remaining H3K4me3
marks accessible to H3 K4 demethylases such as RBP2 and
JARID1C, resulting in their demethylation. We have shown that
increasing the level of CYP33 decreases the level of expression of
MLL target genes and decreases the level of H3K4me3 at target
gene promoters (Figure 6). In addition, increasing the level of
CYP33 also increases the density of H3 at MLL target genes, con-
sistent with a more dense, repressive chromatin state (Figure 6).
The amount of CYP33 available to bind to MLL PHD3 may
be regulated by its binding to RNA. This could provide a
mechanism for regulating gene promoters by moving them to
different nuclear compartments with a high RNA concentration
(transcription factories) or a low RNA concentration (hetero-
chromatin compartments), even in the presence of a constant
average nuclear CYP33 concentration.
Our results also show that the proline isomerase activity of
CYP33isessentialforitsrepressivefunctiononMLLtargetgenes.
On the basis of analogy to Fpr4, which has been shown to iso-
merize histone tail residues to alter epigenetic modifications (42),
FIGURE 6: CYP33 represses transcription of MLL target genes and
changes chromatin modification levels. (A) Expression of HOXA9,
HOXC8,CDKN1B,andC-MYCinHEK293Tcellstransfectedbyan
empty vector (blue) orCYP33-containing plasmid (red). (B) ChIP at
promoters of CDKN1B (top) and HOXC8 (bottom) for probing the
density of histone H3, the change in levels of H3K4me3, and the K9
and K14 acetylation of H3 (H3Ac) upon CYP33 overexpression.
HEK293T cells were transfected with an empty vector (blue) or a
CYP33-containing plasmid (red). IgG was used as a control.
FIGURE 7: PPIase activity is necessary for CYP33-mediated repres-
sion. (A) The expression of MLL target genes was monitored by
Q-RT-PCR after transfection of HEK293T cells with an empty
vector,wild-typeCYP33,andtheCYP33-PPIasemutant.(B)Expres-
sion levelsofthe wild-type and PPIase mutantofCYP33 normalized
toβ2M.(C) Schemeforthechymotrypsin-coupledprolineisomerase
assay (45). (D) Comparison of the cis/trans conversion rates for four
prolines in histone tails with (red) or without (blue) CYP33.6584 Biochemistry, Vol. 49, No. 31, 2010 Park et al.
we tested the ability of CYP33 to isomerize H3 and H4 tail
peptides. Our results show significant activity for both H3P30
and H3P16 and demonstrate an altered histone tail specificity
relative to Fpr4. This activity suggests a mechanism for the
proline isomerase function of CYP33, namely that by means of
isomerization of prolines in the histone tail, CYP33 can effect a
change in the epigenetic modification profile on the H3 tail. The
isomerization of one or more prolines could easily alter the
activity of histone acetyl transferase (HAT), histone deacetylase
(HDAC), histone methyl transferase, or histone demethylase
enzymes at specific loci, resulting in this proposed alteration of
the epigenetic profile. Alternatively, CYP33 may target prolyl-
peptide bonds on MLL itself or on proteins that interact with
MLL.RecruitmentofHDAC1totherepressiondomainofMLL
is enhanced by CYP33 overexpression (15). These mechanisms
are not mutually exclusive. It is possible that Cyp33 targets
different peptide bonds in different proteins and contributes to
repression of MLL target genes by more than one mechanism.
Future efforts in this area will need to focus on testing this array
of possibilities to deduce the specific mechanism.
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FIGURE 8: PHD3usestwoseparatesurfacestobindH3K4me3andCYP33RRM,andtheinteractionsaremutuallyinhibitory.(A)Twosurfaces
with a 180  difference on the MLL PHD3 domain serve for the H3K4me3-binding site (left) and for the RRM-binding site (right). The residues
whose backbone resonances were broadened out (light blue or light green) or significantly shifted (dark blue or dark green) upon complex
formationaredisplayedonthesurface.(B)BindingconstantsoftwoPHD3mutantsmeasuredbyITC.V1617AabrogatesCYP33RRMbinding
affinity∼6.2-foldbutdoesnotsignificantlychangetheaffinityforH3K4me3.W1594AlacksH3K4me3bindingbutdoesnotsignificantlychange
the affinityfor CYP33 RRM.Note thatthese two residuesare located onthe separate surfaces ofPHD3 shown in panel A.(C) Thermodynamic
boxshowingthebindingconstantsforeachinteraction.ThebindingconstantsweremeasuredbyITC.PHD3(62μM)wassaturatedwith540μM
H3K4me3andthentitratedwith635μMCYP33RRM.PHD3(65μM)wassaturatedwith200μMCYP33RRMandthentitratedwith745μM
H3K4me3.
FIGURE 9: ModelfortheroleofMLLPHD3inactivationandrepre-
ssion. Binding of PHD3 to H3K4me3 protects this mark from de-
methylationandpossiblyfacilitatesthepropagationoftheH3K4me3
mark, all leading to activation. When the CYP33 concentration is
high, PHD3 preferentiallybinds toCYP33,resulting intherelease of
H3K4me3 from the MLL complex, loss of SET domain-mediated
H3K4 methylation, increased nucleosome density, and concomitant
repression. In addition, the CYP33 proline isomerase may act on the
histone tail to enhance the addition of epigenetic marks for repression.Article Biochemistry, Vol. 49, No. 31, 2010 6585
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